Cargando…
Metformin: a modulator of bevacizumab activity in cancer? A case report
Recurrent type I endometrial cancer ((EC)) has poor prognosis and demands novel therapeutic approaches. Bevacizumab, a VEGF-A neutralizing monoclonal antibody, has shown clinical activity in this setting. To our knowledge, however, although some diabetic cancer patients treated with bevacizumab may...
Autores principales: | Indraccolo, Stefano, Randon, Giovanni, Zulato, Elisabetta, Nardin, Margherita, Aliberti, Camillo, Pomerri, Fabio, Casarin, Alessandra, Nicoletto, Maria Ornella |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4623111/ https://www.ncbi.nlm.nih.gov/pubmed/25607951 http://dx.doi.org/10.1080/15384047.2014.1002366 |
Ejemplares similares
-
Endovascular interventions for central vein stenosis
por: Agarwal, Anil K.
Publicado: (2015) -
Current progress in ABO-incompatible kidney transplantation
por: Koo, Tai Yeon, et al.
Publicado: (2015) -
RNA sequencing of the nephron transcriptome: a technical note
por: Lee, Jae Wook
Publicado: (2015) -
Organ-on-a-chip and the kidney
por: Kim, Sejoong, et al.
Publicado: (2015) -
Neuro-tracing approach to study kidney innervation: a technical note
por: Lee, Sanghee, et al.
Publicado: (2017)